Biocon Biologics Ltd (BBL), a global leader in biosimilars and a subsidiary of Biocon Ltd, has received European Commission approval for YESINTEK®, a biosimilar of Ustekinumab. This milestone expands treatment options for patients in the European Union (EU).
YESINTEK® is approved for treating plaque psoriasis in adults and children, as well as psoriatic arthritis and Crohn’s disease in adults. Clinical trials confirmed its comparable safety and efficacy to the reference biologic, ensuring patients receive a high-quality alternative at a potentially lower cost.
This approval follows a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on December 14, 2024. With this, Biocon Biologics continues to strengthen its footprint in the global biosimilars market, offering advanced therapies for chronic autoimmune diseases.
